11-hydroxy-N-(n-propyl)noraporphine

RN given refers to parent cpd without isomeric designation; (R)-isomer is a dopamine agonist; (S)-isomer is a dopamine antagonist

Also Known As:

11-OH-NPa; 11-hydroxy-N-(n-propyl)noraporphine hydrochloride, (R)-isomer; 11-hydroxy-N-(n-propyl)noraporphine hydrochloride, (S)-isomer; 11-hydroxy-N-(n-propyl)noraporphine hydroiodide; 11-hydroxy-N-(n-propyl)noraporphine hydroiodide, (+-)-isomer; 11-hydroxy-N-(n-propyl)noraporphine, (+-)-isomer; 11-hydroxy-N-(n-propyl)noraporphine, (R)-isomer; 11-hydroxy-N-(n-propyl)noraporphine, (S)-isomer; 11-hydroxy-N-n-propylnorapomorphine; 11-hydroxy-N-n-propylnoraporphine; 5,6,6a,7-tetrahydro-6-propyl-4H-dibenzo(de,g)quinolin-11-ol

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Benzylisoquinolines: 151
    - Aporphines: 10
      - 11-hydroxy-N-(n-propyl)noraporphine: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - Benzylisoquinolines: 151
        Aporphines: 10
        11-hydroxy-N-(n-propyl)noraporphine: 1
  - 4 or More Rings Heterocyclic Compounds
    - Aporphines: 10
      - 11-hydroxy-N-(n-propyl)noraporphine: 1

Experts

1.	Fisher, Ria: 1 article (01/2016)
2.	Jackson, Michael J: 1 article (01/2016)
3.	Jenner, Peter: 1 article (01/2016)
4.	Lees, Andrew J: 1 article (01/2016)
5.	Lincoln, Louise: 1 article (01/2016)
6.	Neumeyer, John: 1 article (01/2016)
7.	Rose, Sarah: 1 article (01/2016)
8.	Sromek, Anna W: 1 article (01/2016)

Related Diseases

Dyskinesias (Dyskinesia)

01/01/2016 - "In contrast, oral treatment with 11-OH-NPa valerate (0.19 and 0.75 mg/kg) induced a dose-related reversal of motor disability and increased locomotor activity with only mild to moderate dyskinesia. "
01/01/2016 - "Oral administration of 11-OH-NPa valerate produced a rapid reversal of motor disability and, at effective dose levels, had a limited propensity to induce dyskinesia. "
01/01/2016 - "Locomotor activity, motor disability, and dyskinesia were assessed in MPTP-treated marmosets following the administration of apomorphine (0.075 mg/kg, subcutaneous and 0.28 to 1.12 mg/kg, oral) and 11-OH-NPa valerate (0.19, 0.38, and 0.75mg/kg, oral). "

Related Drugs and Biologics

1.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
2.	Valerates
3.	Apomorphine

Related Therapies and Procedures

1.	Oral Administration